Compare HMR & NORD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HMR | NORD |
|---|---|---|
| Founded | 1984 | 1993 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Professional Services |
| Sector | Consumer Discretionary | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.6M | 95.5M |
| IPO Year | 2024 | 2005 |
| Metric | HMR | NORD |
|---|---|---|
| Price | $1.25 | $3.21 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 144.2K | 30.9K |
| Earning Date | 11-17-2026 | 07-25-2017 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.25 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,346.00 |
| Revenue This Year | $67.73 | N/A |
| Revenue Next Year | $0.75 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.73 | $3.38 |
| 52 Week High | $2.02 | $5.28 |
| Indicator | HMR | NORD |
|---|---|---|
| Relative Strength Index (RSI) | 33.66 | 15.40 |
| Support Level | $1.10 | N/A |
| Resistance Level | $1.50 | N/A |
| Average True Range (ATR) | 0.16 | 0.70 |
| MACD | -0.06 | -0.21 |
| Stochastic Oscillator | 15.53 | 8.63 |
Heidmar Maritime Holdings Corp is a commercial and technical management company that operates tanker and dry-bulk vessel pools. The group, along with its subsidiaries, operates as a growing tanker pool company engaged in the commercial management and chartering of crude oil and refined petroleum product tankers. Its lines of business currently include asset management, tanker pooling, commercial and time charters, assisting clients with the buying and selling of ships, and technical management services for individual vessels, which include assistance in technical operations and crewing of the vessel. Its geographic areas are Singapore, the USA, the Marshall Islands, the United Arab Emirates, Germany, Switzerland, and Other.
Nordicus Partners Corp specializes in developing breakthrough therapeutics for diseases with unmet medical needs. The Company focuses on acquiring and developing drugs from biotech companies in the Nordics, a region known for its scientists, life sciences ecosystem, and drug discoveries and developments. Its current portfolio includes the preclinical biotechnology companies Orocidin A/S, Bio-Convert A/S, and NoviThera ApS. The Company is dedicated to developing breakthrough therapeutics in diseases with unmet medical needs, starting with oral disorders. It operates in the segment focused on developing medicines supporting oral health.